Repros Therapeutics

Repros Therapeutics — Investor Presentation (June 2013)

24 slides from Repros Therapeutics's investor presentation, Jun 7, 2013

  1. Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements made by the Company that are not historical facts contained in this release are forward - looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund developme

  3. Slide 3: ANDROXAL Safety Review June 2013

    ANDROXAL Safety Review 6 June 2013

  4. Slide 4: Potential Safety Issues

    Potential Safety Issues • Clomiphene – Cataracts – Increased estrogen (opposes testosterone increase) • Testosterone – Deep Vein Thrombosis (DVTs ) – Prostate Specific Antigen (PSA) Elevation – T level above normal – Decreased sperm count (infertility) – Gynecomastia • Hypogonadism - osteopenia

  5. Slide 5: ANDROXAL Safety Review

    ANDROXAL Safety Review 6 June 2013 ▪ Treatment Emergent Adverse Events (TEAEs) ▪ Discontinuation due to Adverse Events (DCAEs) ▪ Serious Adverse Events(SAEs) ▪ Testosterone ▪ Prostate Specific Antigen (PSA) ▪ Other Safety Issues Related to Testosterone Therapy

  6. Slide 6: ANDROXAL Safety Review Topics and Studies

    ANDROXAL Safety Review TOPICS STUDIES 003: Phase 3 301: Phase 3 300: long - term safety 303: bone density • Treatment Emergent Adverse Events (TEAEs) • Discontinuation due to Adverse Events (DCAEs) • Serious Adverse Events(SAEs) • Testosterone • Prostate Specific Antigen 300: long - term safety

  7. Slide 7: Treatment Emergent Adverse Events

    TREATMENT EMERGENT ADVERSE EVENTS Studies 301, 300, and 303 Study 301 Study 300 Study 303 Preferred Term 12.5 mg (%) 25 mg (%) PBO (%) 12.5 mg (%) 25 mg (%) 12.5 mg (%) 25 mg (%) PBO (%) N 90 22 37 259 240 94 69 104 Any Event 28 23 24 38 44 19 39 30 Upper respiratory infection 6 5 0 6 5 4 6 5 Headac

  8. Slide 8: DC/AEs: Studies 301, 300, 303 and 003

    DC/AEs : Studies 301, 300, 303 (green font indicates single subject) Study 301 Study 300 Study 303 Study 003 12.5 mg 25 mg PBO 12.5 mg 25 mg 12.5 mg 25 mg PBO 12.5 mg 25 mg Androgel PBO N = 90 22 37 259 240 94 69 104 47 50 48 49 Any DCAE (n = ) 0 1 1 5 1 1 2 0 1 1 5 1 PREFERR ED TERM Ocular discomf

  9. Slide 9: Serious Adverse Events Reported in Studies 301, 300, and 303

    Serious Adverse Events Reported in Studies 301, 300, and 303 ( green font indicates single subject) Study 301 Study 300 Study 303 12.5 mg 25 mg PBO 12.5 mg 25 mg 12.5 mg 25 mg PBO n 90 22 37 259 240 94 69 104 Any SAE (number of subjects) 0 0 0 2 5 0 2 Preferred Terms B radycardia K nee arthroplasty

  10. Slide 10: Testosterone Levels

    T ESTOSTERONE Study 300 at 6 - month point 0 200 400 600 800 1000 1200 Plasma Testosterone concentration TESTOSTERONE LEVELS ON LAST DAY OF DOSING (Study 300) 86% in NORMAL RANGE (300 - 1040) No excursions beyond n ormal range at 6 - months

  11. Slide 11: PSA: baseline, end of treatment, follow-up

    PSA: baseline, end of treatment, follow - up Study 300 (only subjects with data after Vis 5) 0 1 2 3 4 5 6 7 PSA ( ng /mL) BASELINE VIS 3, 4, 5, ET VIS 6,7,ET

  12. Slide 12: PSA

    PSA • PSA elevation is NOT an Adverse Drug Reaction • PSA elevation is an expected result of testosterone increase • PSA is not a cancer marker but a normal enzyme • Elevated PSA included in package insert for Axiron • Incidence and magnitude noted in Androxal studies is not alarming and has been re

  13. Slide 13: Other Safety Issues Related to Testosterone Therapy

    OTHER SAFETY ISSUES RELATED TO TESTOSTERONE THERAPY • Cataracts • Osteoporosis • Deep Vein Thrombosis

  14. Slide 14: Safety Profile - Cataracts

    Safety Profile - Cataracts • 1) – After 4 months, nuclear cataract in left eye disappeared, cortical cataract in right eye progressed – Described as age - related progression of senile cataract • 2) – Described as having cataract after 5 months of therapy, but all entries are “0”, same as baseline.

  15. Slide 15: Safety Profile - DVT

    Safety Profile - DVT • Deep Vein Thrombosis – One subject taking 12.5 mg Androxal developed a DVT after a 5 hour flight – Treated with anticoagulants to resolution • No other adverse events suggest incidence of DVT or other thrombotic events

  16. Slide 16: Safety Profile – Bone Health

    Safety Profile – Bone Health • Hypogonadism is associated with osteopenia • Study ZA - 303 captures bone mineral density assessments via DEXA for subjects over one year of Androxal exposure • Some subjects have completed DEXA analyses after 6 months of treatment – Early data suggests that Androxal s

  17. Slide 17: Conclusions

    CONCLUSIONS • Androxal is well tolerated • Findings are consistent with known pharmacology • No new safety issues

  18. Slide 18: Clinical and Regulatory Team

    Clinical and Regulatory Team • J.F. Wernicke, Ph.D., M.D., Chief Medical Officer – 30 years in clinical research – Ph.D. Biochemistry and MD Neurologist – Eli Lilly and Company, Clinical Research and Patient Safety • Jaye Thompson, Ph.D., Senior VP Clinical and Regulatory – Ph.D. Biostatistics – 25

  19. Slide 19: Clinical and Regulatory Team

    Clinical and Regulatory Team • Jennifer Nydell, Androxal Clinical Program Director – 17 years clinical research and development – 13 years Boehringer Ingelheim • Michele Rosner, Clinical Program Director – MS Biological Chemistry and Management – 16 years clinical development – 13 years with Pfizer

  20. Slide 20: Androxal Study Status

    Androxal Study Status Study Target Enrollment/Sites Duration Current Enrollment Top Line Results ZA 300 (Safety Study) 500 28 Sites 6 months Fully Enrolled 182 Completed Q4 2013 ZA-301 (Pivotal) 151 17 Sites 3 months Fully Enrolled Positive results on primary efficacy endpoints ZA-302 (Pivotal) 180

  21. Slide 21: NDA Preparations

    NDA Preparations • Building team – Contracting consultants and acquiring some additional staff • Evaluating and purchasing software and hardware for electronic NDA filing • Conducting audits of key clinical sites and vendors – No findings to date jeopardize data – Completed audit of central laborato

  22. Slide 22: NDA Timeline

    NDA Timeline Q4 2013 Q1 2014 Q2 2014 Q3 2014 NDA Phase I Studies ZA-302 ZA-300 Final Safety Data for ISS ISE Pre-NDA Meeting

  23. Slide 23: Projected Cash Requirements Through H1 2015

    Projected Cash Requirements Through H1 2015 (in millions) 2014 H1 2015 Total Androxal $7.5 $0 $7.5 Proellex $8.0 $6.0 $14.0 General Corporate $8.0 $4.5 $12.5 Total Cash Required Through Androxal Approval $34.0 Assumptions: Androxal - NDA filed in mid - 2014, expected approval mid - 2015; includes FD

  24. Slide 24: Financial Summary

    Financial Summary • Cash and equivalents (as of 4/1/13 - unaudited) $17.2 M • Cash runway: Q1 2014 • Current shares outstanding: 18.7 M shares – Warrants Outstanding – Series A – 877,137 (purchased in unit deal @ $2.45); Series B – 810,496 @ $2.49 exercise price.

Repros Therapeutics — Investor Presentation (June 2013) on 6ix